The relationship between S-adenosylhomocysteine and coronary artery lesions: A case control study

- Plasma SAH concentrations are independently associated with coronary artery lesions among patients undergoing coronary angiography.
- Plasma SAH might be a novel biomarker for the early clinical identification of CVD.

The role of homocysteine (Hcy) in the pathogenesis of coronary artery disease (CAD) is controversial, as decreased Hcy levels have not demonstrated consistent clinical benefits. Recent studies propose that S-adenosylhomocysteine (SAH), and not Hcy, plays a role in cardiovascular disease (CVD). We aimed to assess the relationship between plasma SAH and coronary artery lesions. Participants (n = 160; aged 40-80 years) with chest pain and suspected CAD underwent coronary angiography (CAG) for assessment of coronary artery stenosis, and were assigned to either the atherosclerosis (AS) or CAD group. Plasma SAH and S-adenosylmethionine (SAM) concentrations were measured and the association between coronary artery lesions and SAH was assessed. SAH levels were significantly higher in the CAD group (23.09 ± 2.4 nmol/L) than in the AS group (19.2 ± 1.5 nmol/L). While the AS group had higher values for SAM/SAH (5.1 ± 0.7 vs. 4.1 ± 1.1), levels of SAM, Hcy, folate, and vitamin B12 were similar in the two groups. Coronary artery lesions were associated with SAH (β = 11.8 [95% CI: 5.88, 17.7, P < 0.05]. Plasma SAH concentrations are independently associated with coronary artery lesions among patients undergoing coronary angiography. Plasma SAH might be a novel biomarker for the early clinical identification of CVD.